…
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 1078.00M | 433.00M | 1622.00M | 534.00M | -9046.00M |
| Minority interest | - | 0.00M | 0.00M | 3.00M | 3.00M |
| Net income | 382.00M | 1017.00M | 1479.00M | 1432.00M | -6918.00M |
| Selling general administrative | 4377.00M | 3940.00M | 3435.00M | 3614.00M | 2387.00M |
| Gross profit | 14643.00M | 16779.00M | 8081.00M | 8875.00M | 3215.00M |
| Reconciled depreciation | 1345.00M | 1278.00M | 1350.00M | 1489.00M | - |
| Ebit | 3670.00M | 4024.00M | 2200.00M | 1027.00M | -7911.00M |
| Ebitda | 5015.00M | 5302.00M | 3550.00M | 2516.00M | - |
| Depreciation and amortization | 1345.00M | 1278.00M | 1350.00M | 1489.00M | - |
| Operating income | 3436.00M | 3775.00M | 928.00M | 384.00M | -7911.00M |
| Other operating expenses | 12133.00M | 13937.00M | 7914.00M | 9342.00M | 290.00M |
| Interest expense | 756.00M | 3797.00M | 578.00M | 493.00M | 0.00M |
| Tax provision | 696.00M | -584.00M | 143.00M | -898.00M | - |
| Interest income | 663.00M | 199.00M | 1628.00M | 824.00M | - |
| Net interest income | -93.00M | -3598.00M | 1050.00M | 331.00M | - |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | 696.00M | -584.00M | 143.00M | -898.00M | -2127.00M |
| Total revenue | 15569.00M | 17712.00M | 8842.00M | 9726.00M | 3550.00M |
| Total operating expenses | 11207.00M | 13004.00M | 7153.00M | 8491.00M | 11461.00M |
| Cost of revenue | 926.00M | 933.00M | 761.00M | 851.00M | 335.00M |
| Total other income expense net | -2358.00M | -3342.00M | 694.00M | 150.00M | -1135.00M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | 382.00M | 1017.00M | 1479.00M | 1432.00M | -6919.00M |
| Net income applicable to common shares | 382.00M | 1017.00M | 1479.00M | 1432.00M | -6918.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 99417.00M | 96985.00M | 76465.00M | 56680.00M | 58987.00M |
| Intangible assets | 8577.00M | 9120.00M | 11802.00M | 12999.00M | 14367.00M |
| Other current assets | 865.00M | 427.00M | 651.00M | 499.00M | 480.00M |
| Total liab | 41481.00M | 39517.00M | 24084.00M | 11602.00M | 17407.00M |
| Total stockholder equity | 57936.00M | 57468.00M | 52381.00M | 45075.00M | 41577.00M |
| Deferred long term liab | - | - | - | - | 0.00M |
| Other current liab | 2288.00M | 5822.00M | 1307.00M | 917.00M | 375.00M |
| Common stock | 41335.00M | 41036.00M | 40220.00M | 37479.00M | 36854.00M |
| Capital stock | 41335.00M | 41036.00M | 40220.00M | 37479.00M | - |
| Retained earnings | -8911.00M | -9768.00M | -10785.00M | -12264.00M | -13696.00M |
| Other liab | 7831.00M | 3248.00M | 4646.00M | 7595.00M | 7988.00M |
| Good will | 15306.00M | 15095.00M | 14134.00M | 14365.00M | 14177.00M |
| Other assets | - | 102.00M | 7.00M | - | 0.00M |
| Cash | 66557.00M | 60087.00M | 40008.00M | 15375.00M | 18760.00M |
| Total current liabilities | 4092.00M | 7191.00M | 2985.00M | 2303.00M | 5449.00M |
| Current deferred revenue | 296.00M | 279.00M | 29.00M | 162.00M | - |
| Net debt | -36823.00M | -30816.00M | -23385.00M | -13496.00M | - |
| Short term debt | 176.00M | 193.00M | 170.00M | 175.00M | 2987.00M |
| Short long term debt | - | - | - | 175.00M | 2987.00M |
| Short long term debt total | 29734.00M | 29271.00M | 16623.00M | 1879.00M | - |
| Other stockholder equity | 25512.00M | 26200.00M | 22946.00M | 19860.00M | -7623.00M |
| Property plant equipment | 3791.00M | 3817.00M | 3824.00M | 4120.00M | 2715.00M |
| Total current assets | 69942.00M | 62808.00M | 42018.00M | 19563.00M | 22284.00M |
| Long term investments | - | - | - | 5633.00M | 5444.00M |
| Net tangible assets | 34053.00M | 33253.00M | 26445.00M | 17711.00M | 13033.00M |
| Short term investments | - | 86.00M | - | - | 0.00M |
| Net receivables | 2462.00M | 2241.00M | 1671.00M | 3689.00M | 3044.00M |
| Long term debt | 27981.00M | 27440.00M | 14789.00M | 1704.00M | 3940.00M |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 1628.00M | 1176.00M | 1508.00M | 1211.00M | 2080.00M |
| Total permanent equity | - | - | - | - | 0.00M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00M |
| Accumulated other comprehensive income | - | - | - | - | 0.00M |
| Additional paid in capital | - | - | - | - | 0.00M |
| Common stock total equity | - | - | - | - | 0.00M |
| Preferred stock total equity | - | - | - | - | 0.00M |
| Retained earnings total equity | - | - | - | - | 0.00M |
| Treasury stock | - | - | - | - | 0.00M |
| Non currrent assets other | 1801.00M | 188.00M | 4687.00M | 5633.00M | - |
| Non current assets total | 29475.00M | 34177.00M | 34447.00M | 37117.00M | - |
| Capital lease obligations | 1753.00M | 1831.00M | 1834.00M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 1043.00M | 206.00M | 238.00M | -250.00M | -650.00M |
| Change to liabilities | 315.00M | -984.00M | 61.00M | -258.00M | 185.00M |
| Total cashflows from investing activities | 1043.00M | 278.00M | -150.00M | -246.00M | -3252.00M |
| Net borrowings | - | 29855.00M | 15902.00M | -7061.00M | -3005.00M |
| Total cash from financing activities | -4887.00M | 11123.00M | 20278.00M | -6964.00M | -3274.00M |
| Change to operating activities | 4780.00M | 3001.00M | -683.00M | 848.00M | 1208.00M |
| Net income | 1078.00M | 433.00M | 1622.00M | 534.00M | -6918.00M |
| Change in cash | 6470.00M | 20079.00M | 24633.00M | -3385.00M | -13377.00M |
| Begin period cash flow | 60087.00M | 40008.00M | 15375.00M | 18760.00M | 28281.00M |
| End period cash flow | 66557.00M | 60087.00M | 40008.00M | 15375.00M | 18760.00M |
| Total cash from operating activities | 9952.00M | 7095.00M | 4672.00M | 3441.00M | -6047.00M |
| Issuance of capital stock | 0.00M | 600.00M | 5145.00M | 747.00M | - |
| Depreciation | 1345.00M | 1278.00M | 1350.00M | 1489.00M | 1153.00M |
| Other cashflows from investing activities | 137.00M | 273.00M | 294.00M | 284.00M | -2.00M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | -210.00M | -799.00M | 752.00M | -923.00M | 10.00M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | -4887.00M | 29481.00M | 15133.00M | -650.00M | -213.00M |
| Change to netincome | 2644.00M | 3366.00M | 1570.00M | 1751.00M | 443.00M |
| Capital expenditures | 303.00M | 201.00M | 105.00M | 280.00M | 2231.00M |
| Change in working capital | 5258.00M | -1783.00M | 1364.00M | 258.00M | - |
| Stock based compensation | 700.00M | 713.00M | 626.00M | 384.00M | - |
| Other non cash items | 1571.00M | 6454.00M | -290.00M | 776.00M | - |
| Free cash flow | 9649.00M | 6894.00M | 4567.00M | 3161.00M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SOLTF Sosei Group Corporation |
-0.75 7.14% |
9.75 | - | - | 0.07 | 1.99 | 0.08 | -1.38 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
| Name | Title | Year Born |
|---|---|---|
| Mr. Shinichi Tamura | Founder & Chairman | 1949 |
| Mr. Chris Cargill | Representative Exec. Officer, Pres, CEO & Director | 1984 |
| Mr. Hironoshin Nomura | Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO | NA |
| Mr. Kieran Johnson F.C.A. | Exec. Officer, VP & Chief Accounting Officer | NA |
| Dr. Miles Congreve | Chief Scientific Officer | NA |
| Mr. Kazuhiko Yoshizumi | Exec. Officer, VP & Chief Compliance Officer | 1954 |
| Candelle Chong | VP of Corp. Strategy & Communications | NA |
| Shinichiro Nishishita | VP of Investor Relations & Head of Regulatory Disclosures | NA |
| Dr. Barry Kenny Ph.D. | Chief Bus. Officer of Bus. Devel. | NA |
| Stacey Southall | Associate Director & Head of Biophysics | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.